Home>Topics>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals VRTX

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. HQH, HQL

      Commentary

      Tue, 12 May 2015

      I noticed VRTX is up about $8.75 (7%) in the after-hours market due to the FDA panel recommended approval of its cystic fibrosis drug. VRTX is the third largest holding in each of these Tekla CEF, as last reported.

    2. UPDATE 2-US FDA panel recommends Vertex cystic fibrosis treatment

      Headlines

      Tue, 12 May 2015

      WASHINGTON, May 12 (Reuters) - A U.S. Food and Drug Administration advisory committee on Tuesday recommended approval of Vertex Pharmaceuticals Inc's combination cystic fibrosis therapy, finding it to be safe and effective for patients ages 12 and up.

    3. FDA staff question efficacy of Vertex experimental CF drug in combination

      Headlines

      Fri, 8 May 2015

      May 8 (Reuters) - FDA staff reviewers questioned whether Vertex Pharmaceuticals Inc's experimental cystic fibrosis drug added any benefit over its already approved therapy, Kalydeco, in patients with the most common genetic mutation underlying the disease.

    4. Tiny Corbus looks to take on Vertex with experimental lung drug

      Headlines

      Mon, 4 May 2015

      May 4 (Reuters) - Corbus Pharmaceuticals Holdings Inc's experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's successful treatment, Kalydeco.

    5. From Barron’s, March 9, 2015 (Part 2)

      Commentary

      Sat, 7 Mar 2015

      pg 14]; Foot Locker [ FL ; pg 18]; small-cap Century Communities [ CCS ; pg 26]; new drugs in pipeline [ AMGN, NVS, VRTX ; pg 33]; maritime infrastructure [ Orient Overseas /316.hk; pg 33]; Whirlpool [ WHR ; the CEO spotlight on Jeff Fettig

    6. Five Consensus Views that Could Prove Wrong in 2015

      Headlines

      Tue, 27 Jan 2015

      entails. In future articles, we'll explore other pharma and biotech option opportunities, such as how to use the option market to take advantage of blockbuster drug potential at Vertex Pharmaceuticals VRTX and Keryx Biopharmaceuticals KERX.

    7. Morningstar / portfolio / xray / stock intersector

      Commentary

      Tue, 18 Nov 2014

      surprised that my second largest stock holding is UNP(2.87%) by my FSRFX fund. ACT(2.7%), UPS(2.27%) and VRTX (1.85%) round out the top five. I have a number of my own spreadsheets with charts, but this is one thing that would be

    8. A Favorable Prognosis for This Pharma Stock

      Video Reports

      Thu, 18 Sep 2014

      Stefan Quenneville: We think [TICKER: VRTX ] Vertex Pharmaceuticals ( VRTX ) has a positive moat trend because its recent clinical success in cystic fibrosis positions it as a dominant

      Vertex Pharmaceuticals VRTX found at 0:04

      Stefan Quenneville: We VRTX Vertex Pharmaceuticals ( VRTX ) has a positive moat trend because its recent clinical success in cystic fibrosis positions it as a dominant player in this very
    9. Managing Expectations, Part II

      Headlines

      Tue, 19 Aug 2014

      which may face some tough competition if Albuferon receives Food and Drug Administration approval. We still think Vertex's VRTX Phase II telaprevir holds the most promise among hepatitis C drugs in development. Human Genome Sciences and partner Novartis

    10. Reinvent Your Practice: Alternatives to Traditional Succession Planning

      Headlines

      Fri, 25 Apr 2014

      Worldwide UTIW Vertex Pharmaceuticals VRTX Walt Disney DIS ..... UTi Worldwide Vertex Pharmaceuticals Economic Moat ..... thinks Vertex's VRTX expertise in chronic ..... Analyst Report: Vertex Pharmaceuticals Walt Disney

    « Prev12345Next »
    Content Partners